Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Drops By 17.7%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) saw a large decline in short interest in August. As of August 31st, there was short interest totalling 85,900 shares, a decline of 17.7% from the August 15th total of 104,400 shares. Based on an average daily trading volume, of 1,450,000 shares, the short-interest ratio is currently 0.1 days.

Biodexa Pharmaceuticals Stock Down 4.8 %

Shares of BDRX stock opened at $0.38 on Wednesday. Biodexa Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $8.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.26 and a current ratio of 1.26. The business has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.92.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.